Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07612267 · ClinicalTrials.gov registry record · Phase 4
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
A Phase 4 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT07612267: Clinical Trial Phase 4 study, sponsored by Eli Lilly and Company.
NCT07612267 is a Phase 4 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07612267, a Phase 4 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication. Participation in this study could last up to 94 days, including screening and follow-up period.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
What is known before NCT07612267 opens enrollment
NCT07612267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT07612267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07612267 about?
NCT07612267 is a clinical study titled "A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication". The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication. Participation in this study could last up to 94 days, including screening and follow-up period.
What is the current status of trial NCT07612267?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2026-06. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07612267?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT07612267?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07612267's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia